TTR and familial amyloid neuropathy: Disease-modifying treatments (DMTs) such as tafamidis meglumine (transthyretin stabilizer), patisiran, vutrisiran (small-interfering RNA), and inotersen (antisense oligonucleotide) have been approved for the treatment of ATTRv amyloidosis by multiple regulatory agencies [63, 66].